Hip joint distension in osteoarthrosis. A triple-blind controlled study comparing the effect of intra-articular indoprofen with placebo.

Abstract

In a triple-blind controlled study, significant pain alleviation (p less than 0.01) was registered in patients with osteoarthrosis (OA) of the hip in the first 24 h after hip joint distension. There was no significant difference between treatment with indoprofen (a new non-steroidal anti-inflammatory drug for intra-articular use) and placebo. Pain relief lasted for at least 12 weeks in approximately half of the patients, in whom a significant increase in joint mobility was registered. Intra-articular indoprofen was not superior to placebo as regards pain relief or increased joint mobility. These findings indicate that the effect of a single hip joint distension in OA is due to a mechanical distension of the joint capsule, perhaps involving disruption of local agglutinations, and not due to suppression of inflammation.

• Authors: C Egsmose, B Lund, R Bach Andersen
• Journal: Scandinavian journal of rheumatology (Scand J Rheumatol) Vol. 13 Issue 3 Pg. 238-42 ( 1984) ISSN: 0300-9742 [Print] England
• PMID: 6385228 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article)

Chemical References

• Phenylpropionates
• Placebos
• Indoprofen

Topics

• Adult
• Aged
• Clinical Trials as Topic
• Female
• Hip Joint (pathology)
• Humans
• Indoprofen (administration & dosage, therapeutic use)
• Injections, Intra-Articular
• Male
• Middle Aged
• Osteoarthritis (drug therapy, physiopathology, therapy)
• Pain (drug therapy, etiology)
• Phenylpropionates (therapeutic use)
• Placebos